Tenaya Therapeutics Inc

Price Chart

Risk-Adjusted Performance

Tenaya Therapeutics Inc (TNYA) Price Performance

Tenaya Therapeutics Inc (TNYA) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $0.74, up 6.22% from the previous close.

Over the past year, TNYA has traded between a low of $0.39 and a high of $2.10. The stock has gained 59.8% over this period. It is currently 64.9% below its 52-week high.

Tenaya Therapeutics Inc has a market capitalization of $160.58M.

About Tenaya Therapeutics Inc

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Compare Tenaya Therapeutics Inc

Side-by-side comparison against top Healthcare peers.